SpyGlass Pharma IncSGP
Price$26.50

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Margins

Current

Quality Metrics

Earnings-Beat Rate0.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Ophthalmic Drug-Delivery Candidates$0
View details

Phase 3 trial enrollment expected to complete in 2027, with a planned 505(b)(2) NDA submission to the FDA in 2028.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.